Heidi M. Hagen Vineti Inc.

Heidi is a Co-founder and Chief Strategy Officer for Vineti Inc., a company that is scaling and digitizing cell and gene therapies through an advanced software platform and data analytics. Heidi is also an advisor for a variety of cell therapy companies and currently sits on the Board of Directors for Vericel Corporation, a commercial cell therapy company that markets and produces MACI and Epicel for orthopedic and wound healing indications. In her career, she has overseen operations that have produced more than 100,000 doses of cell therapy.

Heidi has a proven track record in leading operations and commercializing innovative technologies worldwide. She is the former Global COO for SOTIO a.s. in Prague, CZ Republic. Before joining SOTIO she worked at Dendreon for ten years as Senior Vice President of Operations, where she was responsible for Technical Operations, among other duties. She built the commercial U.S. Provenge facilities and operations (the first active cellular immunotherapy approved in both the US and EU) and led all operations for the U.S. and the EU. Before Dendreon, she spent ten years with Immunex Corporation. Heidi has a B.S. in Cell and Molecular Biology, M.S. in Bioengineering, and M.B.A. from the University of Washington.